1 / 13

CANCER AUTOVACCINE (CAV) New specific active anticancer agent

CANCER AUTOVACCINE (CAV) New specific active anticancer agent. From Science To Business 11-12 October 2006, Kyiv G.P.Potebnya Telephone : 259-91-94; 259-08-75 E-mail : nauka@onconet.kiev.ua R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine

faith
Télécharger la présentation

CANCER AUTOVACCINE (CAV) New specific active anticancer agent

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CANCER AUTOVACCINE (CAV) New specific active anticancer agent From Science To Business 11-12 October 2006, Kyiv G.P.Potebnya Telephone : 259-91-94; 259-08-75 E-mail : nauka@onconet.kiev.ua R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine Kyiv 03022, Ukraine

  2. Proprietary information statement • The technology material presented in this talk is available for licensing or joint product development. • None of the slides contain any confidential or proprietary information.

  3. Problem Description & Market Need Cancer Diseases (on 100 000 populations): • In the world:210 • Central and East Europe:349 • Ukraine:341(162000 in year 2005) • Russia:314 CAV could be used for treatment 125000 of all cases of cancers in Ukraine.

  4. Brief technology descriptionprof. D.G.Zatula • CAV prepared from autologous tumor cells and products of synthesis of a saprophytic microorganism B.subtilis B-7025; • CAV introduced by hypodermic injections. The complete course consists of 3 injections with 7 day's interval. The revaccination will be carried out through 1 and 6 months; • CAV prevented relapses and metastasis after surgery treatment, increased overall and relapse-free survival of patients; • CAV is recommended as independent immunotherapeutic agent in the postoperative period.

  5. Advantages • Wide specter cancer’s forms, where CAV treatment could be used. • CAV produced from own cells of patients, so there is no any risk of SPID, or other’s infection diseases and it’s need no control methods concerning alien infection agents. • CAV is most effective at the late stages of cancer. • Effectiveness of CAV treatment may be compared, or better, then chemo- or radiotherapy, but without so characteristic for them toxic effects. • Cost of production and treatment by CAV more lower then chemo- or radiotherapy. • Combination to other methods of therapy: • After radical operation (early stages of disease, the absence of metastasis) an effective utilization CAV without chemo- or radiotherapy. If it is necessary carryings out courses of chemo- or the radiotherapies immunotherapy by CAV may be started in 18-21 days after their end.

  6. EFFICACY ANTICANCER AUTOVACCINE DURING COMPLEX THERAPY IN STOMACH CANCER PATIENTS (Overall survival) • CAV treatment enhanced 5-years survival (57% versus 31%), 10-years survival (50% versus 27%); • CAV treatment of stomach cancer patients has no analogous.

  7. EFFICACY ANTICANCER AUTOVACCINE DURING COMPLEX THERAPY IN LUNG CANCER PATIENTS (Overall survival) • CAV treatment enhanced 5-years survival (39% versus 10%); • CAV treatment of lung cancer patients has no analogous

  8. Stage of development (clinical tests if medical) and international patents • CAV treatment were supported by National Academy of Science of Ukraine, Ministry of Health and Farmcommittee of Ukraine • It was obtained permission (certificate) for using CAV in Ukraine’s clinics • Now 8 clinics in country successfully use this treatment

  9. Targeted Market Segment • CAV could be used for treatment of most spread cancers forms Among them: For men:For women: Lung cancer - 21%Breast cancer - 21% Stomach cancer- 10%Cervical cancer - 6% Rectum cancer- 6%Rectum cancer- 5% Colon cancer- 5%Colon cancer - 6%

  10. In comparison with existing products or methodsSummary of 5-year' s survivals patients with rectum cancer (III stage), who were undertaken different forms of treatments

  11. Competitive MatrixIn comparison with another autologous anticancer vaccines (colon cancer –5 years survival)

  12. Opportunities 1. In common work to obtain licences for CAV treatment in EC countries, USA and Russia 2. In common work to produce and use CAV in this countries

  13. Contact information G.P.Potebnya Telephone : 259-91-94; 259-08-75 E-mail : nauka@onconet.kiev.ua R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Science, Ukraine

More Related